Callum Dew is a Senior Scientist in Microbiology, New Modalities and Parenteral Development for Pharmaceutical Technology & Development Operations at AstraZeneca UK. In this white paper, he discusses how his organization has used Enzyme Indicators (EIs) to optimize the VPHP decontamination cycle and what results this has led to.
He details some of the challenges involved in the manufacturing process for sterile pharmaceuticals and the importance of streamlining these activities to deliver improved productivity without the need for large-scale investment.
The white paper also explains:
Download the full white paper below to learn more about what EI technology has achieved for AstraZeneca and how it could help your business.
Read about the advantages and benefits of using our Enzyme Indicators for your H₂O₂ bio-decontamination validation processes.
Biological Indicators vs Enzyme Indicators at a glance.
Presentations, white papers, webinars, shared articles, project summaries and product analysis.
Luminox House,
48 Holmethorpe Avenue
Redhill, Surrey
RH1 2NL
United Kingdom
Tel: +44 (0) 1737 924 900
Fax: +44 (0) 1737 924 901